Updates the July battlecard. The DTC launch changed the primary design problem. The positioning angle has shifted accordingly.
Trigger
Maven's VP of Design search — confirmed backfill after Eli Horne's June departure — has been live for nearly three months, reporting to CPO Jason Lee. Horne wrote the replacement JD and scoped it as product design, brand design, and research under one leader. Confidence: high.
Window
Three weeks of peak leverage. Lee is speaking at Maven's Onward conference September 30. He likely wants this hire deep in final rounds before he's on stage presenting the clinical product roadmap. After Onward, the search either fills or drifts into Q4. Move this week.
What this means for the design org
The VP inherits a built function. Horne stood up Maven's AI design practice, launched the consumer brand, and left behind two visible team leads: Shweta Grampurohit on product design and Elle Abarca on brand (Creative Director). The incoming VP is governing and expanding an existing org, not building one from scratch.
Maven's nationwide DTC launch in May reshaped the design surface. The VP now oversees two distinct user experiences — employer-sponsored members arriving through benefits and direct consumers paying out of pocket — on a platform running Maven Intelligence, an AI orchestration layer with OpenAI and Google LLMs behind clinical guardrails. The July card was right to call this a governance mandate. The DTC launch layered dual-surface, AI-embedded, regulated-platform complexity on top of it.
Rubric
Company: 9
| Dimension | Score | Signal |
|---|---|---|
| AI centrality | +2 | Platform-wide AI orchestration, strategic bet but not core product |
| Stage | 2 | Series F at $1.7B, pre-IPO but past the C–E sweet spot |
| Design ceiling | 2 | Broad VP mandate but design absent from leadership page |
| Trajectory | 3 | DTC expansion, 28M covered lives, Maven Intelligence, accelerating clinical partnerships |
Role: 11
| Dimension | Score | Signal |
|---|---|---|
| Comp | 3 | $250K–$350K posted base plus equity; pre-IPO Series F, though dilution and late-stage preferences limit equity upside |
| Scope | 2 | Broad mandate, CPO ceiling |
| Craft depth | 2 | Management-heavy VP |
| AI exposure | 2 | AI-adjacent, not AI-native design |
| Portfolio value | 2 | Solid healthcare domain, not frontier AI |
Company clears Act at 9. Role at 11 misses the 12+ Act threshold — craft depth and AI exposure are the gaps. But the live search and closing window override the score. If you want Maven, treat it as Act and move now.
Your angle
Narrative fit: Allē's dual-surface redesign — 30M consumer members and 40K provider practices on a single platform with fundamentally different trust models — is the closest published analog to Maven's post-DTC reality. The employer-sponsored member trusts Maven through their benefits package. The direct consumer trusts Maven through brand, outcomes, and price comparison against retail alternatives. You designed for exactly this split at Allē and delivered 3.2× redemption rate and $42 CAC. Lead with Allē.
Support with Thermo Fisher ($20M+ margin, 6 pharma partners, 100% adoption) for regulated-platform credibility. Add the Trust essay for AI governance depth — Maven Intelligence's clinical guardrails map directly to the Decision Gate and Output Review handoffs. If the Human-Agent System Design artifacts are published at junochen.com before outreach, they strengthen this angle considerably — interaction models for workflows where clinician and AI share authority over care decisions would give you visual proof most candidates can't match. If they're not live yet, lead with the Trust essay's Decision Gate framework and Carrier IQ's regulated-industry approval surfaces. Do not reference artifacts a hiring manager cannot find.
The brand gap
The VP owns brand design through Elle Abarca. Your portfolio doesn't include brand-function leadership as a named capability. Name this in your own head before anyone else names it for you.
Counter-evidence: Allē's consumer brand work, Equinox+'s five premium brands (0→MVP), and Alibaba's full platform redesign including brand expression demonstrate brand-aware product leadership. You can govern a brand function through an experienced creative director without being a brand specialist yourself. Don't claim to be one.
Move anyway. A posting that asks for product + brand + research + AI leadership in one seat and stays open for three months has almost certainly taught the committee something about the market. The recalibration is predictable: they've learned that the regulated-product-plus-AI combination is harder to find than brand leadership, and they've become more flexible on brand accordingly. Your profile fits the recalibrated criteria better than the original posting suggests.
Competitive landscape
- Healthcare design leader (Oscar, Ro, Hims, Teladoc pedigree): strong domain match, but likely underperforms on AI governance depth and dual-surface proof at your scale. Confidence: moderate.
- Brand-forward design leader (DTC brand background): strong brand match, weaker on regulated platform, AI, and enterprise scale. The direct threat is a healthcare candidate who also has brand oversight. Confidence: moderate.
- Enterprise platform leader (Salesforce, Adobe pedigree): strong scale match, weaker on healthcare domain, AI credibility, and 0→1 speed. Confidence: moderate.
Your differentiation is the combination. Three months of open search is the evidence that the combination is scarce.
Who to contact
Jason Lee, CPO — linkedin.com/in/jasonjaeholee
Public fingerprint: Thin. His most recent signal is a May reshare of the DTC launch: "Everyone deserves access to quality care. Proud of the team for this incredible milestone." No bylines, talks, or original posts on design philosophy. He's listed as a speaker at Onward (Sept 30) but no session details are published yet. The available hook is Maven-level (DTC launch, Maven Intelligence) rather than Lee-specific.
Warm path: Unresolved. Eli Horne is the strongest potential connector — he wrote the JD, publicly credited Lee, and is now outside Maven. Sequoia and General Catalyst are secondary paths through Maven's investor network. No apparent BCG DV or Alibaba network overlap with Maven's executive team, but your BCG DV healthcare work (Thermo Fisher, Allē/Allergan) may connect to Maven's broader healthcare ecosystem through former colleagues. Worth a manual check. Check your LinkedIn for mutual connections with Horne and Lee before sending anything. If you have a Horne connection, use it for a direct introduction.
Channel: Warm intro through Horne if the connection exists. Cold LinkedIn DM to Lee as fallback.
Outreach messages
Subject line: Dual-surface design after Maven's consumer launch
Warm message (through Horne or mutual connection):
"[Name] suggested I reach out — Maven's consumer expansion created a design problem I've spent real time on: two user populations with fundamentally different trust models on a single platform. As Product Design Director at BCG Digital Ventures, I led the Allē redesign for Allergan Aesthetics — 30M consumer members and 40K provider practices, 3.2× redemption rate — and the structural challenge was the same: designing for both without collapsing the differences. I'd welcome 20 minutes on how you're thinking about the dual-surface challenge post-consumer launch."
Cold message (to Lee):
"Your May post on Maven's consumer launch — 'everyone deserves access to quality care' — is a design problem as much as a clinical one when employer-sponsored members and direct consumers now share the same platform with different trust models and decision patterns. As Product Design Director at BCG Digital Ventures, I led a dual-surface redesign at Allergan Aesthetics (Allē — 30M consumer members, 40K provider practices, 3.2× redemption) and separately built AI governance for clinical-grade decision surfaces, most recently as Head of Product at TinyFish. Would 20 minutes work to discuss the post-consumer-launch design mandate?"
What not to say:
- Don't reference Horne's departure or call this a backfill. It signals you're reading the org chart rather than the product challenge.
- Don't lead with AI governance alone. The July angle was right for July. The DTC launch changed the primary problem. Leading with AI when the committee has spent three months looking for product + brand + research + AI breadth sounds like you're addressing one quarter of the mandate.
Cover letter
Maven's hardest design problem right now is that the May consumer launch created two fundamentally different user relationships on the same platform, and the design function needs a leader who can hold both without collapsing the differences. Employer-sponsored members arrive with coverage context and trust anchored in their benefits package. Direct consumers arrive paying out of pocket, comparing Maven against retail health alternatives, evaluating trust through brand and outcome signals that have nothing to do with an employer.
As Product Design Director at BCG Digital Ventures, I led the Allē redesign for Allergan Aesthetics — a dual-surface platform serving 30M consumer members and 40K provider practices with completely different trust models, decision patterns, and success metrics. The redesign delivered 3.2× redemption rate and $42 CAC by treating each surface as its own design problem while maintaining a coherent system underneath. Also at BCG Digital Ventures, I led Thermo Fisher's mySupply platform from zero to $20M+ annual margin recovery across six pharma partners — a regulated, multi-stakeholder environment where design decisions carried compliance weight. Most recently as Head of Product at TinyFish, I shipped an AI-native enterprise platform from 0 to 1 within three months, working daily with agent traces, auditability, and governance challenges that map to Maven Intelligence's clinical AI guardrails.
I moved to product to build AI from zero. I've returned to design because I want to apply that technical depth to a specific, high-stakes vertical — and Maven's intersection of clinical care, consumer health, and embedded AI is exactly that domain.
My portfolio at junochen.com includes the Allē and Thermo Fisher case studies, the Trust essay "Trust Is the New Interface" — a framework for designing decision gates and human authority in AI-mediated workflows — and three live agentic AI applications including Carrier IQ, which demonstrates regulated-industry approval surfaces. I'd welcome a conversation about how you're approaching the dual-surface design challenge after the consumer launch.
Resume emphasis
Craft depth: 2 (VP management role). AI exposure: 2 (AI-adjacent).
- Lead with Allē — dual-surface, regulated, consumer + provider, 3.2× redemption, $42 CAC. Direct analog to Maven's post-DTC challenge.
- Follow with Thermo Fisher — regulated platform, pharma, $20M+ margin, 0→1, 100% adoption. Domain credibility.
- Third: Alibaba — enterprise scale, $50B+ GMV, +20% transactions. Scale proof.
- TinyFish in header as bridge: "Most recently, Head of Product at TinyFish (enterprise web agent platform, Series A)" — one line on shipping 0→1 in 3 months, agent traces in production.
- Add Carrier IQ from Agentic Labs for AI credibility — regulated industry + agentic automation is the strongest match.
- Trim: Red Cross (not healthcare). Equinox+ only if the brand question surfaces in conversation.
Post-outreach signals
Maven is a growth-stage healthcare platform with a three-month-old search. Calibrate accordingly:
- Response within 3–5 business days is normal. Faster than that means they're ready to close — prioritize prep immediately.
- Silence past 7 business days: follow up at day 8 with an Onward hook. Reference a specific agenda topic and connect it to your dual-surface framing.
- Lee engages the dual-surface framing specifically: strong signal. Respond within 24 hours and deepen the thread.
- Recruiter-only reply: the message landed but didn't cut through to Lee. Get to him in the screen.
- No reply after follow-up: the search may be further along than the posting suggests. Move to Watch and monitor for a refresh.
The non-obvious thing
Shweta Grampurohit's April hiring post recruited for "AI-powered journeys and agentic UX." The product design team is already building in agentic terms. The VP hire is expected to govern and scale an AI-fluent team that's already shipping — not to introduce AI to the design org. Prepare for "how would you set the quality bar for AI-powered care experiences already in production," not "how would you bring AI into a design practice." The Trust essay's Decision Gate handoff applied to clinical AI is your answer — and if the forward-looking artifacts are live at junochen.com, they give you visual proof most competing candidates won't have.
Warning signs
Design's structural weight is informal. The Tier Playbook flagged this in July: design is absent from Maven's public leadership page. A VP reporting to the CPO, with no design presence on the executive roster, means the function's strategic influence depends on Lee's advocacy. Ask in the first conversation: "How does design's perspective reach the executive team today?" Frame it as scope.
The rubric says Watch. Role score of 11 falls short of Act. Craft depth and AI exposure are the specific gaps — this is a management-heavy, AI-adjacent role. If you're optimizing for hands-on work and frontier AI exposure, Maven ranks below your AI-native targets. If the healthcare domain and the dual-surface challenge are what pull you, the closing window justifies moving now despite the score.
- Maven's Onward conference agenda: Lee is listed as a speaker at Onward on September 30, but no session assignment or quotation has been published yet — monitor for session details that would give you a Lee-specific hook before outreach.
- Maven Intelligence's clinical guardrails: Fierce Healthcare reported that Maven uses NVIDIA NeMo Guardrails and multidisciplinary clinical review before releasing AI capabilities — worth understanding the governance model deeply before any interview conversation about quality bars.
- Shweta Grampurohit's role scope: A third-party directory labels her Director of Product Design since August 2025, but LinkedIn doesn't expose the formal title — clarifying her scope and authority in the first conversation tells you what the VP actually inherits.
- Maven's high-risk pregnancy outcomes: A recent Maven Institute study reported 32% fewer NICU admissions and 10% fewer C-sections compared to national benchmarks — useful clinical-outcome context if Lee steers the conversation toward Maven's evidence base.